Literature DB >> 20063122

Gastric ulcer in a child treated with deferasirox.

Tiene Bauters1, Veerle Mondelaers, Hugo Robays, Kathleen Hunninck, Barbara de Moerloose.   

Abstract

We present a patient with thalassemia major who developed a gastric ulcer, probably related to the use of deferasirox. Although gastric ulcer is mentioned as infrequent adverse event in the scientific product information of deferasirox, in our current knowledge, this is the first case-report on this adverse drug reaction. The severity of this event justifies the reporting of this case.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20063122     DOI： 10.1007/s11096-009-9357-1

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN： 0928-1231


  7 in total

1.  Adverse drug reactions: definitions, diagnosis, and management.

Authors:  I R Edwards; J K Aronson
Journal:  Lancet       Date:  2000-10-07       Impact factor: 79.321

Review 2.  Deferasirox--an oral agent for chronic iron overload.

Authors:  Heidi E Vanorden; Tracy M Hagemann
Journal:  Ann Pharmacother       Date:  2006-05-30       Impact factor: 3.154

3.  Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.

Authors:  Renzo Galanello; Antonio Piga; Gian Luca Forni; Yves Bertrand; Maria Loreta Foschini; Elena Bordone; Giovanbattista Leoni; Antonella Lavagetto; Antonietta Zappu; Filomena Longo; Henry Maseruka; Nicola Hewson; Romain Sechaud; Rossella Belleli; Daniele Alberti
Journal:  Haematologica       Date:  2006-10       Impact factor: 9.941

4.  A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

Authors:  Maria Domenica Cappellini; Alan Cohen; Antonio Piga; Mohamed Bejaoui; Silverio Perrotta; Leyla Agaoglu; Yesim Aydinok; Antonis Kattamis; Yurdanur Kilinc; John Porter; Marcello Capra; Renzo Galanello; Slaheddine Fattoum; Guillermo Drelichman; Carmelo Magnano; Monica Verissimo; Miranda Athanassiou-Metaxa; Patricia Giardina; Alexandra Kourakli-Symeonidis; Gritta Janka-Schaub; Thomas Coates; Christiane Vermylen; Nancy Olivieri; Isabelle Thuret; Herbert Opitz; Catherine Ressayre-Djaffer; Peter Marks; Daniele Alberti
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

Review 5.  Deferasirox.

Authors:  Janice L Stumpf
Journal:  Am J Health Syst Pharm       Date:  2007-03-15       Impact factor: 2.637

6.  Oral iron chelation and the treatment of iron overload in a pediatric hematology center.

Authors:  Jean L Raphael; M Brooke Bernhardt; Donald H Mahoney; Brigitta U Mueller
Journal:  Pediatr Blood Cancer       Date:  2009-05       Impact factor: 3.167

Review 7.  Long-term efficacy and safety of deferasirox.

Authors:  Maria Domenica Cappellini
Journal:  Blood Rev       Date:  2008-12       Impact factor: 8.250
  7 in total
  3 in total

1.  An Unusual Cause of Gastrointestinal Perforation in an Adolescent Patient With Beta-Thalassemia on Deferasirox and SARS-CoV-2 Infection.

Authors:  Devkishan Chauhan; Yakup Kilic; Jonathan P Segal; Neil Patel; Louis Koizia
Journal:  J Hematol       Date:  2021-04-27

2.  Perforated duodenal ulcer: a rare complication of deferasirox in children.

Authors:  Sunil Kumar Yadav; Vipul Gupta; Ashraf El Kohly; Wasmi Al Fadhli
Journal:  Indian J Pharmacol       Date:  2013 May-Jun       Impact factor: 1.200

3.  Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.

Authors:  Janet L Kwiatkowski
Journal:  J Blood Med       Date:  2011-09-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.